9 Second Quarter 2023 Financial Results AUGUST 2, 2023 INTRODUCTION AYVAKIT PERFORMANCE KEY PORTFOLIO MILESTONES Q2 2023 FINANCIAL PERFORMANCE Not for promotional use Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candi dates ...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Jenna Cohen - VP, IR Kate Haviland - CEO Philina Lee - CCO Fouad Namouni - President, R&D Mike Landsittel - CFO Christy Rossi - COO Becker Hewes - CMO Conference Call Participants Brad Canino - Stifel Dane Leone - Raymond James Reni Benjamin - JMP Securities Eun Yang - Jefferies Marc Frahm - TD Cowen Salveen Richter - Goldman Sachs Michael Schmidt - Guggenheim Partners Ami Fadia - Ne ...

Table of Contents The Company evaluated the Zai Lab agreement to determine whether it is a collaborative arrangement in the scope of ASC 808. The Company concluded that the Zai Lab agreement is a collaborative agreement under ASC 808 as both parties are active participants in the clinical trials and are exposed to significant risks and rewards of those activities under the Zai Lab agreement. The Company determined that the Zai Lab agreement contained two material components: (i) licenses granted to Zai Lab ...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Jenna Cohen - Senior Director and Head, Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President, Research & Development Christina Rossi - Chief Operating Officer Conference Call Participants Reni Benjamin - JMP Securities Brad Canino - Stifel ...

4. Marketable Securities | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------|-------|--------------------|-------------------|-------|-----------------------|-------|--------------| | thousands): \nMarch 31, 2023 | | Amortized \nCost | Unrealized \nGain | | Unrealized \nLosses | | Fair \nValue | | Marketable securities, available-for-sale: | | | | | | | | | U.S. government agency securities | $ | 314,891 | | 28 | (2,117) | $ | 312,802 | | U.S. treasury obligat ...

Financial Data and Key Metrics Changes - For the full year 2022, total revenues were $204 million, including $111 million in net product revenues from AYVAKIT and $93 million in collaborations and license revenues, exceeding the high end of the 2022 total revenue guidance of $200 million [46][73] - Total operating expenses were $723.7 million for the full year, with Q4 operating expenses showing a quarter-over-quarter decline from Q3 as the company continues to leverage operating efficiencies [47][48] - The company expects operating expenses to grow moderately in Q1 2023, driven by preparations for the ISM launch and planned manufacturing investments [48] Business Line Data and Key Metrics Changes - AYVAKIT net product revenue doubled year-over-year in 2022, achieving $111 million, with Q4 revenues at $30.1 million, of which $26.3 million came from the U.S. [18][46] - The company anticipates AYVAKIT net product revenues of $130 million to $140 million in 2023, representing a more than 20% increase year-over-year [20][73] Market Data and Key Metrics Changes - The U.S. accounted for the majority of AYVAKIT product sales, with nearly 500 patients on AYVAKIT by the end of 2022 [8][34] - The company is preparing for the ISM launch, targeting approximately 7,500 patients with moderate to severe ISM, who are actively seeking treatment [36][40] Company Strategy and Development Direction - The company aims to expand its leadership in systemic mastocytosis and advance its clinical stage pipeline focused on best-in-class investigational therapies [13][31] - The strategy includes engaging a broader provider base for ISM patients and maintaining strong patient access to therapy [22][40] - The company is focused on achieving a sustainable financial profile while executing on a range of opportunities [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for AYVAKIT and the anticipated launch in ISM, highlighting the strong medical need and motivated patient base [40][128] - The company is optimistic about capturing the significant ISM opportunity, supported by a strong cash position of over $1 billion [15][74] Other Important Information - The company has received EMA validation for its type 2 variation for AYVAKIT and ISM, bringing it closer to the important indication expansion and launch in Europe [69] - The FDA issued a partial clinical hold on the VELA trial due to visual adverse events, but the company is working closely with the FDA to resolve this issue [45][120] Q&A Session Summary Question: What is the overlap between current prescriber base of AYVAKIT and potential ISM patients? - The company indicated that among the top 350 prescribers, there are nearly 400 moderate to severe ISM patients who could rapidly start AYVAKIT upon approval [76][88] Question: What is the current thinking regarding vision events and the CDK2 program? - Management stated that the FDA is working cooperatively to modify the protocol and informed consent regarding the vision events observed [56][120] Question: How does the company view the early trajectory for ISM? - The company does not anticipate an initial launch bolus but expects gradual growth driven by increased disease awareness and advanced patient identification capabilities [126][128] Question: What is the current payer coverage for ISM? - The company reported strong payer coverage with virtually no access challenges for SM patients, and they do not expect a new code for ISM [153][183] Question: How is the sales force adapting to focus on allergists? - The company has expanded its field force to engage a broader provider base, including allergists, and has achieved over 40% awareness of AYVAKIT among target prescribers [149][150]

Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of ...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - MD, Chief Medical Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Conference Call Participants Ernie Rodriguez - Cowen and Company Dane Leone - Raymond James Andrea Tan - Goldman Sachs Pete ...

Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of Regi ...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Christy Rossi - Chief Operating Officer Philina Lee - Chief Commercial Officer Becker Hewes - MD, Chief Medical Officer Mike Landsittel - Chief Financial Officer Conference Call Participants Marc Frahm - Cowen Dane Leone - Raymond James Elizabeth - Goldman Sachs Reni Benjamin - JMP Secur ...